Inovio Q3 net loss widens on non-cash warrant liabilities

Inovio Pharmaceuticals

10/11/2025 21:29

Overview

Inovio Q3 2025 net loss widens to $45.5 mln, driven by non-cash warrant liabilities

Operating expenses decreased to $21.2 mln from $27.3 mln in Q3 2024

Outlook

Inovio projects cash will support operations into Q2 2026

Result Drivers

R&D EXPENSES - Decrease in R&D expenses due to lower costs for INO-3107 manufacturing and clinical studies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.87
Q3 Net Income
-$45.50 mln
Q3 Operating Expenses
$21.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is $7.50, about 71.7% above its November 7 closing price of $2.12

Press Release: ID:nPn4SyL5La

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)